{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-025099","form_type":"8-K","ticker":"NUVB","cik":"0001811063","company_name":"Nuvation Bio Inc.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.976396+00:00","generated_at":"2026-05-26T22:58:30.740073+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Dr. Jerry Wang exits AnHeart Therapeutics CEO role after taletrectinib milestones achieved","bullets":["Dr. Wang departed as CEO of AnHeart Therapeutics, a Nuvation Bio subsidiary, on Feb. 12, 2025.","Departure follows China NMPA approval of taletrectinib for advanced ROS1-positive NSCLC.","Also follows FDA acceptance and priority review of NDA for taletrectinib in advanced ROS1-positive NSCLC.","Dr. Wang resigned from Nuvation Bio board effective Feb. 11, 2025; no disagreement with company.","Role eliminated as redundant after successful integration of AnHeart Therapeutics post-merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-025099","json":"https://secwatch.observer/filing/0001193125-25-025099.json","markdown":"https://secwatch.observer/filing/0001193125-25-025099.md","text":"https://secwatch.observer/filing/0001193125-25-025099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/d839065d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T22:58:30.740073+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0ae9afbc25","claim":"Jerry Wang departed as Chief Executive Officer of AnHeart Therapeutics at Nuvation Bio Inc..","evidence_excerpt":"On February 12, 2025, Dr. Jerry Wang, the Chief Executive Officer of AnHeart Therapeutics, a Nuvation Bio Inc. (the “Company”) company, departed the Company following the achievement of key Company goals","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Executive Officer of AnHeart Therapeutics"}]},{"claim_id":"40fc524739","claim":"Jerry Wang resigned as Member of the Board of Directors at Nuvation Bio Inc..","evidence_excerpt":"Additionally, on February 11, 2025, Dr. Wang notified the board of directors (the “Board”) of his resignation as a member of the Board, effective February 11, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1811063/000119312525025099/0001193125-25-025099-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Member of the Board of Directors"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}